

5th Congress of the European Academy of Neurology

Oslo, Norway, June 29 - July 2, 2019

Teaching Course 10

Clinical science in muscle disorders (Level 2)

Diaphragmatic weakness

Pascal Laforet Paris, France

Email: pascal.laforet@psl.aphp.fr



Diaphragmatic weakness

Pr Pascal LAFORÊT

Centre de référence des maladies neuromusculaires Nord/Est/Île-de-France

Service de Neurologie, Hôpital Raymond-Poincaré, Garches INSERM U1179 « End:icap », Université Versailles Saint-Quentin-en-Yvelines

EAN OSLO 2019







Disclosures

- Grants and research support from Sanofi Genzyme, Valerion Therapeutics
- Honoraria/consultation fees from Sanofi Genzyme, Amicus Therapeutics, Sparks Therapeutics
- Participation in company-sponsored speakers' bureau from Sanofi Genzyme, Amicus Therapeutics, and Sparks Therapeutics

Diagnosis and management of neuromuscular disorders: basic principles

- Assessment of limbs and axial muscle weakness
- Systematic cardiac examination : ECG + echocardiography
- Systematic evaluation of respiratory function : PFT +/- blood gas

These parameters are crucial for diagnosis and the follow-up of the patients

Respiratory insufficiency in neuromuscular disorders

- Usually occurs in adults with advanced stages of the disease:
 - Duchenne, SMA, Limb-girdle muscular dystrophies (sarcoglycanopathies, FKRP...)
- But also occasionally at disease onset, or as a predominant symptom:
 - Some muscle disorders may reveal through acute respiratory failure, and thus referred by pneumologists or intensive care units doctors





















Clinical cases of myopathies revealed by severe diaphragmatic weakness











Other symptoms • Diffuse but moderate muscle weakness: 4/5 Diagnosis: • Myotonic dystrophy type 1 /Steinert disease • Most frequent myopathy in adults • * these symptoms were not detected by the GP and pneumologist, and the patient was not complaining about

Respiratory insufficiency in DM1/Steinert disease

- Very frequent manifestation of the disease even in patients able to ambulate unaided
- Inaugural complication in some cases
- · Major cause of morbidity/mortality in DM1
- · Patients most often don't complain of symptoms
- PFT + blood gas measurement should be systematically performed











Emergency care

- Transfer to hospital intensive care unit
- Intubation and mechanical ventilation
- Bronchial fibroscopy and aspiration

Neurological examination

- Proximal lower limbs muscle weakness :
 Muscle testing: 4/5 on MRC scale
- Absence of atrophy
- No fasciculation
- Presence of DTR, and absence of pyramidal syndrome
- · No sensory deficit
- No ophtalmoplegia



- Delayed motor milestones:
 - walked at age of 2 years
- Difficulties for sport activities at school : – always exempted
- Progressive lower limbs weakness since 2 years with difficulties for climbing stairs and raising from a chair :
 - professional redeployment !







Ancillary exams

- CPK: 300 UI/L
- ENMG:
 - Myopathic pattern
 - Pseudo-myotonic discharges
- ECG: normal, absence of conduction or rhythm anomaly
- Echocardiography :
 - Absence of dilated or hypertrophy cardiomyopathy
 - Normal LV ejection fraction
- Acid alpha-glucosidase deficiency in leucocytes

Late-onset Pompe disease or acid maltase deficiency (LOPD)

- First descriptions by Hudgson P. *et al.* (Brain, 1968) and Engel AG. (Brain, 1970)
- Pelvic girdle weakness which may mimic muscular dystrophy or other myopathies
- Respiratory insufficiency due to diaphragmatic paralysis during the course of the disease
- Inaugural respiratory failure as first symptoms of the disease in some patients (Lightman NI and Schooley RT, Chest, 1977; Trend PS *et al.*, Brain, 1985)
- Possibility of prolonged survival with respiratory assistance

Late-onset Pompe disease: frequent diaphragmatic involvement at various ages







Absence of correlation between severity of limb muscle weakness and diaphragmatic involvement

Case n°2 : follow-up

- Weaning from tracheostomia after a few months
- Severe diaphragmatic weakness assessed by by PFT : - CV = 1270 ml (34 %)
 - MIP = 12 cm H2O, MEP = 30 cm H2O
- Nocturnal ventilation
- Enzyme replacement therapy since 2015 (Myozyme ®) : 20 mg/kg infusion every other week
- Stabilization of diaphragmatic weakness and walking difficulties



Case n°3

- 27-year-old man of Portuguese origin
- Family history: parents are first cousins
- Regular sports activities: swimming and fitness
- 26 years: occurrence of dyspnea and muscle fatigability during exercise leading to interruption of sport activities
- 27 years: coma and cardio-pulmonary arrest during skiing
- Intubation and mechanical ventilation:
 - Right basal pneumonia
 - Acute respiratory distress

- Transfer to Garches hospital
- Severe diaphramatic weakness assessed by diaphragmatic ENMG
- PFT:
 - Sitting VC : 1960 ml 35 % /Supine VC : 1270 ml 22 %
 - MIP = 37 cm H2O, MEP = 135 cm H2O
- Clinical examination:
 - Left peroneal nerve palsy
 - Mild weakness of ilio-psoas
 - No ophtalmoplegia or swallowing difficulties
- Normal CK levels
- Normal acid alpha-glucosidase activity

ENMG

 Sensory-motor axonal neuropathy asymmetric with denervation

Neuromuscular biopsy:

- Nerve:

- Major axonal involvement
- Absence of amylosis

– Muscle:

- Atrophy with denervation
- Agregates on Gomori Trichrome



ENMG

 Sensory-motor axonal neuropathy asymmetric with denervation

Neuromuscular biopsy:

- Nerve:
 - Major axonal involvement
 - Absence of amylosis
- Muscle:
 - Atrophy with denervation
 - Agregates on Gomori Trichrome





 Sensory-motor axonal neuropathy asymmetric with denervation

• Neuromuscular biopsy:

- Nerve:

- Major axonal involvement
- Absence of amylosis
- Muscle:
 - Atrophy with denervation
 - Agregates on Gomori Trichrome

- PFT:

- Sitting VC
 - 1960 ml 35 %
- Supine VC
 - 1270 ml 22 %
- MIP = 37 cm H2O, MEP = 135 cm H2O

















Take-home messages (1)

- Systematically evaluate respiratory function in case of suspicion of NMD, and collaborate with dedicated physiologist and pneumologists
- Ideally always perform PFT with:
 - sitting and supine VC assessment
 - MIP, MEP and SNIP
 - +/- polysomnography
- Respiratory muscle involvement may occur in most NMD at various stages of the disease course according to the etiology
- Ventilation may help to prolong life for years and decades...

Take-home messages (2)

- Respiratory insufficiency may be predominant in specific disorders, showing the importance of establishing a correct diagnosis
- Main "myopathic" causes (Naddaf E and Milone M, Muscle and Nerve, 2017):
 - Pompe diseas
 - Myotonic dystrophy type 1
 - Myofibrillar myopathies: Desmine, Filamin C, FHL1
 - Cytoplasmic body myopathy: Titin
 - Multi-minicore disease (SEPN1), MEGF10 related myopathies
 - MELAS, Laminopathy, Centronuclear myopathy

Take-home messages (3)

- Action to be taken in a patient with "isolated" diaphragmatic impairment :
 - Assess the neurogenic or myopathic origin if possible: clinical history and examination, ENMG of limbs and diaphragm (?)
 - Perform blood analysis for CK, lactate, acid alpha-glucosidase, anti-Rach and anti-Musk Ab
 - Discuss the muscle biopsy even in the absence of muscle weakness and in case of normality of all ancillary exams

